Interview with Dr Erik Joseph Stratmand, Chair of the AAD Scientific Assembly Committee.
What are the highlights from AAD 2018?
Dr Stratman: “First of all, it is very exciting that we have one of the largest groups of registrants ever, with physicians from every state in the US and over 99 other countries. As for the highlights, we are surely living in the golden age of psoriasis therapies. There is a large number of new psoriasis drugs and as dermatologists want to learn about new therapies, that is certainly one of the hot areas. Furthermore, new therapies for very severe atopic dermatitis (AD) are being discussed. There are also some practice management topics dermatologists have to face; for example, access to drugs which are...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Improvement in impact of genital psoriasis on sexual activity with use of ixekizumab Next Article
Better gastrointestinal tolerability with biologics than the conventional therapy »
Table of Contents: AAD 2018
Psoriasis: an update
What's hot in atopic dermatitis
Pearls of the posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.